drugset / Trial / NCT00362037
I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
* To evaluate Blood Pressure (BP) reduction to the targeted values (BP ≤ 140/90 mm Hg in non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients). * To emphasize and to evaluate the benefit of Irbesartan in the reduction of left ventricular mass index in hypertensive patients with left ventricular hypertrophy. * To demonstrate safety of Irbesartan in this population.
Timeline
- Start
- 2006-03
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irbesartan | Small molecule | 150 mg | Oral |
| Subject | Irbesartan | Small molecule | 300 mg | Oral |
| Background | Hydrochlorothiazide | Unknown | 12.5 mg | Oral |